Get the Stockscreener App
17.25
1.54%
-0.27
Pre-market:
16.01
-1.24
-7.19%
Xencor Inc stock is traded at $17.25, with a volume of 612.61K.
It is down -1.54% in the last 24 hours and down -27.28% over the past month.
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
See More
Previous Close:
$17.52
Open:
$17.57
24h Volume:
612.61K
Relative Volume:
0.97
Market Cap:
$1.21B
Revenue:
$133.62M
Net Income/Loss:
$-177.37M
P/E Ratio:
-5.9689
EPS:
-2.89
Net Cash Flow:
$23.50M
1W Performance:
-6.76%
1M Performance:
-27.28%
6M Performance:
-3.36%
1Y Performance:
-9.73%
1-Day Range:
$16.79
$17.68
1-Week Range:
$16.79
$19.17
52-Week Range:
$15.31
$27.24
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
17.25 | 1.21B | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-16-24 | Reiterated | BTIG Research | Buy |
| Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-23 | Initiated | BofA Securities | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-21-22 | Initiated | SMBC Nikko | Outperform |
| Dec-15-21 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Apr-12-19 | Initiated | Guggenheim | Buy |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Mar-15-19 | Initiated | Raymond James | Outperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Mar-02-17 | Initiated | Instinet | Neutral |
| Mar-02-17 | Reiterated | Wedbush | Outperform |
| Oct-04-16 | Initiated | Piper Jaffray | Overweight |
| Dec-22-15 | Initiated | Canaccord Genuity | Buy |
| Aug-05-15 | Reiterated | MLV & Co | Buy |
| Feb-12-15 | Reiterated | Oppenheimer | Outperform |
| Jan-28-15 | Reiterated | MLV & Co | Buy |
| Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
Xencor (XNCR) Loses -25.22% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
BlackRock, Inc. Increases Stake in Xencor Inc. - GuruFocus.com
Ratios Reveal: Breaking Down Xencor Inc (XNCR)’s Financial Health - The Dwinnex
Xencor's SWOT analysis: biotech stock faces mixed outlook amid pipeline progress - MSN
Xencor Inc [XNCR] Stock sold by Insider Montgomery Alan Bruce for $0.36 million - Knox Daily
Some Confidence Is Lacking In Xencor, Inc. (NASDAQ:XNCR) As Shares Slide 27% - Simply Wall St
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Xencor (NASDAQ:XNCR investor five-year losses grow to 50% as the stock sheds US$96m this past week - Yahoo Finance
Xencor, Inc. (NASDAQ:XNCR) Short Interest Up 21.4% in January - Defense World
Xencor: Substantial Promise, Slow Progress (NASDAQ:XNCR) - Seeking Alpha
(XNCR) Investment Analysis - Stock Traders Daily
Xencor Insiders Sold US$891k Of Shares Suggesting Hesitancy - Simply Wall St
Xencor's SWOT analysis: biotech stock navigates pipeline progress amid market challenges - MSN
Xencor (NASDAQ:XNCR) Trading Down 3.9%Should You Sell? - MarketBeat
Down -21.69% in 4 Weeks, Here's Why Xencor (XNCR) Looks Ripe for a Turnaround - MSN
JPMorgan Chase & Co. Acquires 3,635 Shares of Xencor, Inc. (NASDAQ:XNCR) - Defense World
After Plunging -20.27% in 4 Weeks, Here's Why the Trend Might Reverse for Xencor (XNCR) - Yahoo Finance
Xencor (NASDAQ:XNCR) Stock Price Down 3.8%What's Next? - MarketBeat
Xencor Becomes Oversold (XNCR) - Nasdaq
Xencor (XNCR) Upgraded to Strong Buy: Here's What You Should Know - MSN
Here's Why Xencor (XNCR) is Poised for a Turnaround After Losing -23.68% in 4 Weeks - Yahoo Finance
Xencor Highlights Progress in Drug Development Pipeline - TipRanks
Xencor (NASDAQ:XNCR) Trading Down 9.3%Here's Why - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of "Buy" by Brokerages - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
How To Trade (XNCR) - Stock Traders Daily
Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Principal Financial Group Inc. - Defense World
Is Xencor (NASDAQ:XNCR) Using Too Much Debt? - Simply Wall St
Geode Capital Management LLC Raises Position in Xencor, Inc. (NASDAQ:XNCR) - Defense World
26,831 Shares in Xencor, Inc. (NASDAQ:XNCR) Purchased by Sanctuary Advisors LLC - Defense World
Sanctuary Advisors LLC Takes $540,000 Position in Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
Barclays PLC Raises Stake in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Barclays PLC Increases Stake in Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
Intrahepatic Cholangiocarcinoma Pipeline Insights 2024: Therapies, Clinical Trials, and Key Companies involved by DelveInsight | Xencor, Relay Therapeutics, Kinnate Biopharma, Forma Therapeutics - The Globe and Mail
Fmr LLC Buys 12,729 Shares of Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor, Inc. (NASDAQ:XNCR) Stake Increased by Jane Street Group LLC - MarketBeat
State Street Corp Reduces Stake in Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
When (XNCR) Moves Investors should Listen - Stock Traders Daily
Xencor (NASDAQ:XNCR) Earns Overweight Rating from Analysts at Wells Fargo & Company - Defense World
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Xencor's SWOT analysis: biotech stock balances promise and challenges - Investing.com
Xencor's SWOT analysis: biotech stock balances promise and challenges By Investing.com - Investing.com Canada
Wells Fargo Initiates Coverage of Xencor (XNCR) with Overweight Recommendation - MSN
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):